Population analysis of myelosuppression profiles using routine clinical data after the ICE (Ifosfamide/Carboplatin/Etoposide) regimen for malignant gliomas

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 4402-4412

  Yano, Yoshitaka ^a   Kodawara, Takaaki ^b   Hongo, Haruyuki ^b   Yano, Ikuko ^b   Kishi, Yo ^a   Takahashi, Jun ^a   Inui, Ken Ichi ^b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Cancer chemotherapy; Erlang distribution; ICE; Modeling and simulation; Myelosuppresion; Pharmacodynamics; Population analysis

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; GLIOBLASTOMA; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; MALE; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; RETICULOCYTE COUNT; THROMBOCYTE COUNT;

EID: 70349640536     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21731     Document Type: Article

References (32)

1. Veal GJ, Coulthard SA, Boddy AV. 2003. Chemotherapy individualization. Invest New Drugs 21:149-156.
2. Karlsson MO, Port RE, Ratain MJ, Sheiner LB. 1995. A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57:325-334.
3. Karlsson MO, Molnar V, Bergh J, Freijs A, Larsson R. 1998. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 63:11-25. (Pubitemid 28070182)
4. Minami H, Ratain MJ, Ando Y, Shimokata K. 1996. Pharmacodynamic modeling of prolonged administration of etoposide. Cancer Chemother Pharmacol 39:61-66. (Pubitemid 26400661)
5. Minami H, Sasaki MY, Saijo N, Ohtsu T, Fujii H, Igarashi T, Itoh K. 1998. Indirect response model for the time course of leucopenia with anticancer drugs. Clin Pharmacol Ther 64:511-521. (Pubitemid 28531595)
6. Friberg LE, Brindley CJ, Karllson MO, Devlin AJ. 2000. Models of schedule dependent haematological toxicity of 20-deoxy-20-methylidenecytidine (DMDC). Eur J Clin Pharmacol 56:567-574.
7. Fetterly GJ, Tamburlin JM, Straubinger RM. 2001. Paclitaxel pharmacodynamics: Application of a mechanism-based neutropenia model. Biopharm Drug Dispos 22:251-261.
8. Minami H, Sasaki Y, Watabnabe T, Ogawa M. 2001. Pharmacodynamic modeling of the entire time course of leucopenia after a 3-hour infusion of paclitaxel. Jpn J Cancer Res 92:231-238. (Pubitemid 32237100)
9. Minami H. 2005. A point, a line, or an area? Which is the most important in the pharmacological analysis of cancer chemotherapy? J Clin Oncol 23:405-406.
10. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. 2002. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713-4721. (Pubitemid 36025290)
11. Friberg LE, Karlsson MO. 2003. Mechanistic models for myelosuppression. Invest New Drugs 21:183-194.
12. Leger F, Loos WJ, Bugat R, Mathijssen RHJ, Goffinet M, Verweij J, Sparreboom A, Chatelut E. 2004. Mechanism-based models for topotecan-induced neutropenia. Clin Pharmaclo Ther 76:567-578.
13. Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO. 2005. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23:413-421. (Pubitemid 46224216)
14. van Kesteren C, Zandvliet AS, Karlsson MO, Mathôt RA, Punt CJ, Armand JP, Raymond E, Huitema AD, Dittrich C, Dumez H, Roché HH, Droz JP, Ravic M, Yule SM, Wanders J, Beijnen JH, Fumoleau P, Schellens JH. 2005. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs 23:225-234. (Pubitemid 40684947)
15. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. 2006. Clinical application of a semi-mechanistic- physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57:427-435. (Pubitemid 43087585)
16. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. 2006. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: Comparison across anticancer drugs. Clin Cancer Res 12:5481-5490. (Pubitemid 44497264)
17. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. 2006. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57:412-426. (Pubitemid 43087584)
18. Sandström M, Lindman H, Nygren P, Johansson M, Bergh J, Karlsson MO. 2006. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 58:143-156.
19. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P. 2008. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther 83:130-143.
20. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JH, Huitema AD. 2008. PK/PD model of indisulam and capecitabine: Interaction causes excessive myelosuppression. Clin Pharmacol Ther 83:829-839. (Pubitemid 351704912)
21. Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, Delattre JY. 1996. Treatment of recurrent malignant supratentorial gliomas with ifosifamide, carboplatin and etoposide: A phase II study. Eur J Cancer 32:2229-2235. (Pubitemid 27008495)
22. Fouladi M, Baruchel S, Chan H, Grant R, Malkin D, Weitzman S, Greenberg ML. 1998. Use of adjuvant ICE chemotherapy in the treatment of anaplastic ependymomas. Childs Nerv Syst 14:590-595. (Pubitemid 28503606)
23. López-Aguilar E, Sepú lveda-Vildósola AC, Rivera- Márquez H, Cerecedo-Díaz F, Hernández-Contreras I, Ramón-García G, Diegopérez-Ramírez J, Santacruz-Castillo E. 2000. Preirradiation ifosfamide, carboplatin, and etoposide for the treatment of anaplastic astrocytomas and glioblastoma multiforme: A phase II study. Arch Med Res 31:186-190.
24. López-Aguilar E, Sepú lveda-Vildósola AC, Rivera- Márquez H, Cerecedo-Díaz F, Valdés-Sánchez M, Delgado-Huerta S, Wanzke-del Angel V, Ramón-García G, Rodríguez-Jiménez H, Hernández-Contreras I, Santacruz-Castillo E, Romo-Rubio HA. 2003. Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children. Childs Nerv Syst 19:818-823.
25. Kerbusch T, Matht RA, Keizer HJ, Ouwerkerk J, Rodenhuis S, Schellens JH, Beijnen JH. 2001. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. Eur J Clin Pharmacol 57:467-477. (Pubitemid 32930147)
26. Krejcie TC, Jacquez JA, Avram MJ, Niemann CU, Shanks CA, Henthorn TK. 1996. Use of parallel Erlang density functions to analyze first-pass pulmonary uptake of multiple indicators in dogs. J Pharmacokinet Biopharm 24:569-588.
27. Niemann CU, Henthorn TK, Krejcie TC, Shanks CA, Enders-Klein C, Avram MJ. 2000. Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol. Clin Pharmacol Ther 67:342-350. (Pubitemid 30246809)
28. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711-726. (Pubitemid 47477040)
29. Rousseau A, Léger F, Le Meur Y, Saint-Marcoux F, Paintaud G, Buchler M, Marquet P. 2004. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: Comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 26:23-30. (Pubitemid 38140906)
30. Sun YN, Jusko WJ. 1998. Transit compartments versus Gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci 87:732-737.
31. Mager DE, Jusko WJ. 2001. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 70:210-216.
32. Sheiner LB, Beal SL. 1981. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512.